Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolioParis, October 19, 2023. Sanofi has delivered the first medicines from its Global Health Unit&rsquo... Read More
Sanofi
2 years ago ⋅ English ⋅ 8 min read
Newsroom
TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously publ... Read More
Sanofi
2 years ago ⋅ English ⋅ 7 min read
Newsroom
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis- Patients treated with amlitelimab experienced up to 61.5% improvemen... Read More
Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease

New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease- Findings include long-term data of up to nearly three year... Read More
Sanofi
2 years ago ⋅ English ⋅ 7 min read
Newsroom
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment- TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative coliti... Read More
Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli- Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of se... Read More